Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 7Terminated 2Active not recruiting 2Withdrawn 1Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 1

Conditions

Uterine Cervical Neoplasms 2Neuroectodermal Tumors, Primitive, Peripheral 2Small Cell Lung Carcinoma 1Sarcoma 1Retinoblastoma 1Prostatic Neoplasms 1Platinum-Refractory Fallopian Tube Carcinoma 1Neuroblastoma 1Neoplasm Metastasis 1Lymphoma 1Lung Neoplasms 1Glioma 1Central Nervous System Neoplasms 1Brain Neoplasms 1Advanced Solid Tumors 1

Interventions

Radiosurgery 7Oxaliplatin 7Docetaxel 7Paclitaxel 5Fluorouracil 5Nivolumab 4Magnetic Resonance Spectroscopy 4Gemcitabine 4Carboplatin 4Capecitabine 4Trastuzumab 3Radiotherapy 3Radiation 3Leucovorin 3Erlotinib Hydrochloride 3Cyclophosphamide 3Cetuximab 3Bevacizumab 3spartalizumab 2sipuleucel-T 2repotrectinib 2pembrolizumab 2pazopanib 2orteronel 2fludarabine 2atezolizumab 2aldesleukin 2Temozolomide 2Surveys and Questionnaires 2Sunitinib 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Withdrawn × Neoplasm Metastasis × Topotecan × Clear all
NCT01736800 2017-09-19

Phase II Trial of Chemotherapy With Temodar With Topotecan for CNS Metastasis of Solid Tumors

The Methodist Hospital Research Institute

Phase 2 Withdrawn
CNS

Brain Neoplasms, Neoplasm Metastasis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡